Karmustin Pliva

Carmustine, the active ingredient in Karmustin Pliva, is a nitrosourea alkylating agent presented as an injectable formulation for intravenous use. It is used in oncology to treat primary brain tumors such as glioblastoma multiforme, Hodgkin's lymphoma, melanoma and a range of other solid tumours.

GNH USA supplies Karmustin Pliva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, transplant units and pharmacies worldwide under strict quality standards. The company ensures reliable logistics and regulatory compliance for cross‑border shipments.

Carmustine is employed in chemotherapy regimens targeting malignant cells of the central nervous system and selected hematologic and solid tumours. - Primary brain tumors (e.g., glioblastoma multiforme): reduces tumor growth and prolongs survival. - Hodgkin's lymphoma: contributes to disease remission in combination protocols. - Melanoma: used as part of multi‑agent therapy for advanced disease. - Other solid tumors: provides cytotoxic activity against various metastatic cancers.

Carmustine therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset. - Myelosuppression: reduced blood cell counts. - Alopecia: hair loss. - Fatigue: persistent tiredness.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe infection: opportunistic infections due to immunosuppression. - Secondary malignancies: risk of therapy‑related cancers.

Prior to initiating Carmustine, clinicians should evaluate patient status and implement monitoring to mitigate risks. - Monitor blood counts: perform complete blood count before each dose. - Assess lung function: baseline pulmonary evaluation and periodic imaging. - Avoid use in patients with known hypersensitivity to nitrosoureas. - Use caution in renal or hepatic impairment: adjust dosing and monitor organ function. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Carmustine may interact with other agents, influencing toxicity or therapeutic efficacy.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: increases risk of severe bone‑marrow suppression. - Radiation therapy: combined use can exacerbate tissue damage and pulmonary toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Antiepileptic drugs (e.g., phenytoin): can alter Carmustine metabolism. - Live vaccines: immunosuppression may reduce vaccine efficacy.